Cardiology AdvisorAHA Scientific Statement Outlines Infective Endocarditis Management

✅ Guideline Update

The American Heart Association has released an updated scientific statement addressing diagnosis, imaging, antimicrobial therapy, and procedural management of infective endocarditis (IE), replacing its prior 2015 guidance. The statement incorporates advances in microbiologic testing, supports use of the 2023 Duke/ISCVID diagnostic criteria, provides updated recommendations regarding echocardiographic evaluation, and reviews evolving evidence regarding partial oral therapy, long-acting antimicrobial agents, and surgical timing. The document emphasizes multidisciplinary management through dedicated endocarditis teams and individualized treatment planning.

Clinical Considerations

• The statement endorses the 2023 Duke/ISCVID criteria, which incorporate molecular diagnostic techniques and expanded imaging findings and generally improve diagnostic sensitivity compared with the historical modified Duke criteria.
• Echocardiography remains the first-line imaging modality for suspected infective endocarditis, with transesophageal echocardiography (TEE) playing a central role in prosthetic valve disease, cardiac implantable electronic device infections, and selected native-valve cases.
• Advanced microbiologic diagnostic testing may facilitate earlier pathogen identification and support earlier initiation of targeted antimicrobial therapy.
• Intravenous antibiotics remain the preferred initial treatment strategy. For carefully selected patients, continuation-phase options may include partial oral therapy, ongoing intravenous therapy, or long-acting injectable lipoglycopeptides.
• The statement notes consensus that gentamicin-associated toxicity outweighs potential benefit in staphylococcal prosthetic-valve endocarditis, while other antimicrobial questions remain dependent on organism-specific management and multidisciplinary review.
• Surgical timing should be individualized through collaboration between cardiology, cardiac surgery, infectious disease, neurology, and neurosurgery teams, particularly when neurologic complications are present.

Practice Applications

• Incorporate the 2023 Duke/ISCVID criteria into diagnostic evaluation of suspected infective endocarditis when appropriate.
• Utilize TEE early in patients with prosthetic valves, cardiac implantable electronic devices, or complex presentations where diagnostic certainty is required.
• Consider advanced microbiologic testing to support organism identification and targeted antimicrobial selection.
• Evaluate eligibility for partial oral therapy using multidisciplinary review rather than routine application.
• Coordinate management through dedicated endocarditis teams when surgical intervention, neurologic complications, or complex antimicrobial decisions are being considered.